This wiki has undergone a migration to Confluence found Here
<meta name="googlebot" content="noindex">

Difference between revisions of "Biomedical Research and Regulation (BR&R)"

From HL7Wiki
Jump to navigation Jump to search
 
(21 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 +
<div style="background-color: white; border: 1px solid red; margin: 4px; padding: 2px; font-weight: bold; text-align: center;">
 +
Current Content related to this page can be found on Confluence [https://confluence.hl7.org/display/BRR/Biomedical+Research+and+Regulation Here]</div>
 +
 
{| style="width:100%; background-color:transparent;"
 
{| style="width:100%; background-color:transparent;"
 
|-  
 
|-  
 
| style="vertical-align:top"| <!-- LEFT COLUMN -->
 
| style="vertical-align:top"| <!-- LEFT COLUMN -->
===Welcome ===
 
Welcome to the Biomedical Research and Regulation (BR&R) Work Group Wiki Site. 
 
  
=== Leadership ===
+
==Content from here will move to Confluence very soon==
Co-Chair: Boris Brodsky; +1 301-796-5179, [mailto:boris.brodsky@fda.hhs.gov brodsky@fda.hhs.gov]
+
[https://confluence.hl7.org/display/BRR/Biomedical+Research+and+Regulation Follow this link to Confluence]
  
Co-Chair: Edward Helton; +1 301-480-4290, [mailto:heltone2@mail.nih.gov heltone2@mail.nih.gov]
+
=== Conference Calls and Minutes ===
 +
'''Regular conference calls take place every 2nd Tuesday between Working Group Meetings from 1000-1100 hour Eastern time.'''
  
Co-Chair: John Kiser; +1 847-937-3725, [mailto:john.kiser@abbvie.com john.kiser@abbvie.com]
+
*Dial-in Number (United States): (515) 739-6161
 +
*Access Code: 547970
 +
*International Dial-in Numbers: https://www.freeconferencecall.com/wall/biomedrr-cc#international
 +
 +
You can also join using your computer.
 +
 +
* [https://join.freeconferencecall.com/biomedrr-cc BR&R Online Meeting Link:]
  
Co-Chair: Vada Perkins; +1 2028102610, [mailto:vada@idglobally.com vada@idglobally.com]
+
*Or, enter online meeting ID on desktop app: biomedrr-cc
  
Project Facilitator: Mead Walker
+
There is a [https://gforge.hl7.org/gf/project/esc/docman/FreeConferenceCall.com%20Pilot/HL7_TipSheet_For_FreeConferenceCall.pdf Tip Sheet here]
 +
 +
All active participants '''and''' other interested individuals are invited to join us for this call.
  
Publishing Facilitator: Myron Finseth
+
===='''[[BR&R Conference call minutes|Conference call agendas and minutes]]''' are posted here====
  
Vocab Facilitator: Julie James
+
[http://www.hl7.org/Special/committees/rcrim/minutes.cfm Link to BR&R WG minutes on hl7.org]
 
 
=== Conference Calls and Minutes ===
 
 
 
Dates:
 
 
 
Time:               
 
  
Phone Number:       
 
  
Participant Passcode: 
+
=== Projects ===
 +
The following are links to specific areas for BR&R sponsored projects
  
[http://www.hl7.org/Special/committees/rcrim/minutes.cfm Link to BR&R WG minutes on hl7.org]
+
[[CRN – FHIR Investigation and Implementation Guide]]
  
 
=== Mission ===
 
=== Mission ===
Line 39: Line 43:
 
The basic charter of the Orders and Observation work group is to continue to support the ongoing development of Version 2.x and ensuring that equivalent functionality is present in HL7 Version 3.0.
 
The basic charter of the Orders and Observation work group is to continue to support the ongoing development of Version 2.x and ensuring that equivalent functionality is present in HL7 Version 3.0.
  
== Work Products and Contributions to HL7 Processes ==
+
=== Leadership ===
 +
Co-Chair: Boris Brodsky; +1 301-796-5179, [mailto:boris.brodsky@fda.hhs.gov brodsky@fda.hhs.gov]
 +
 
 +
Co-Chair: Edward Helton; +1 301-480-4290, [mailto:heltone2@mail.nih.gov heltone2@mail.nih.gov]
 +
 
 +
Co-Chair: Myron Finseth; +1 763-242-3703 [mailto:myron.finseth@medtronic.com myron.finseth@medtronic.com]
 +
 
 +
Co-Chair: Hugh Glover; Skype: hugh_bw, [mailto:hugh_glover@bluewaveinformatics.co.uk hugh_glover@bluewaveinformatics.co.uk]
 +
 
 +
Project Facilitator: Mead Walker
 +
 
 +
Publishing Facilitator: Myron Finseth
 +
 
 +
Vocab Facilitator: Julie James
 +
 
 +
=== Work Products and Contributions to HL7 Processes ===
 
The BR&R performs the bulk of its work through projects with a clear line of sight to its scope. Examples include BRIDG (domain analysis model supporting research) and RPS (exchange message supporting medical product application submissions to regulators).  
 
The BR&R performs the bulk of its work through projects with a clear line of sight to its scope. Examples include BRIDG (domain analysis model supporting research) and RPS (exchange message supporting medical product application submissions to regulators).  
  
Line 46: Line 65:
 
The BR&R will seek to assure that related or supportive standards produced by other HL7 groups are robust enough to accommodate their use in regulated clinical research through participation as appropriate, including ballots. The group will also monitor information interchange standards developed outside of HL7, and attempt harmonization of information content and representation of such standards with the HL7 content and representation.
 
The BR&R will seek to assure that related or supportive standards produced by other HL7 groups are robust enough to accommodate their use in regulated clinical research through participation as appropriate, including ballots. The group will also monitor information interchange standards developed outside of HL7, and attempt harmonization of information content and representation of such standards with the HL7 content and representation.
 
   
 
   
The BR&R’s charge includes the maintenance of BR&R-produced standards until their useful life has been exceeded, either through discontinuance of use or through supersession by later versions of the standard. The portfolio of standards will be reviewed annually for active use, obsolescence, and potential need for change. When a standard is identified for withdrawal, the BR&R will make efforts to communicate to users or potential users of that standard well in advance of any withdrawal action.  
+
The BR&R’s charge includes the maintenance of BR&R-produced standards until their useful life has been exceeded, either through discontinuance of use or through supercession by later versions of the standard. The portfolio of standards will be reviewed annually for active use, obsolescence, and potential need for change. When a standard is identified for withdrawal, the BR&R will make efforts to communicate to users or potential users of that standard well in advance of any withdrawal action.  
 
   
 
   
 
The BR&R will develop specifications using the principles and language of the Services Aware Interoperability Framework (SAIF) Canonical Definition (CD) and the restrictions and specializations of the HL7 SAIF Implementation Guide (IG) to ensure traceability from conceptual to logical to implementable specifications.
 
The BR&R will develop specifications using the principles and language of the Services Aware Interoperability Framework (SAIF) Canonical Definition (CD) and the restrictions and specializations of the HL7 SAIF Implementation Guide (IG) to ensure traceability from conceptual to logical to implementable specifications.
Line 52: Line 71:
 
The term “regulated” or “regulation” refers to human and animal medical products and foods regulation.
 
The term “regulated” or “regulation” refers to human and animal medical products and foods regulation.
  
== Formal Relationships with Other HL7 Groups ==
+
=== Formal Relationships with Other HL7 Groups ===
 
Clinical Genomics
 
Clinical Genomics
 
Clinical Interoperability Council
 
Clinical Interoperability Council
Line 67: Line 86:
 
Structured Documents
 
Structured Documents
  
== Formal Relationships with Groups Outside of HL7 ==
+
=== Formal Relationships with Groups Outside of HL7 ===
 
The BR&R maintains liaison relationships with appropriate national and international standard bodies subject to the approval of the HL7 Board, including at minimum CDISC and ISO TC 215 (and by reference, CEN TC 251).
 
The BR&R maintains liaison relationships with appropriate national and international standard bodies subject to the approval of the HL7 Board, including at minimum CDISC and ISO TC 215 (and by reference, CEN TC 251).
  
== BR&R BRIDG Re-architecture and Usability Subgroup ==
+
=== BR&R BRIDG Re-architecture and Usability Subgroup ===
The objective of this BR&R subgroup is to develop a plan to improve the usability of the BRIDG UML model
+
The objective of this BR&R subgroup is to develop a plan to improve the usability of the BRIDG UML model.
  
 
Deliverables:
 
Deliverables:
Line 80: Line 99:
  
  
[[Subgroup Working Documents (minutes, slides, agendas, etc.)]]
+
[[Subgroup Working Documents]]
 +
 
 +
 
 +
 
 +
===TCB and BR&R Lab Model Discussions===
 +
 
 +
[[Report_back_from_Meeting_Tue_Feb 20th, 2018]]
 +
 
 +
[[Report_back_from_Meeting_Wed_Apr 18th, 2018]]
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
  
 
{{WG Category}}
 
{{WG Category}}

Latest revision as of 18:29, 26 April 2019

Current Content related to this page can be found on Confluence Here

Content from here will move to Confluence very soon

Follow this link to Confluence

Conference Calls and Minutes

Regular conference calls take place every 2nd Tuesday between Working Group Meetings from 1000-1100 hour Eastern time.

You can also join using your computer.

  • Or, enter online meeting ID on desktop app: biomedrr-cc

There is a Tip Sheet here

All active participants and other interested individuals are invited to join us for this call.

Conference call agendas and minutes are posted here

Link to BR&R WG minutes on hl7.org


Projects

The following are links to specific areas for BR&R sponsored projects

CRN – FHIR Investigation and Implementation Guide

Mission

The BR&R workgroup areas of interest encompass clinical and translational research, both regulated and non-regulated, and the subsequent regulatory submissions and information exchanges to bring new products to market and to ensure safe use throughout the product lifecycle. BR&R creates and promotes standards to facilitate biomedical research and any subsequent regulatory evaluation of the safety, efficacy and quality of medical products that may arise from research.

Charter

The basic charter of the Orders and Observation work group is to continue to support the ongoing development of Version 2.x and ensuring that equivalent functionality is present in HL7 Version 3.0.

Leadership

Co-Chair: Boris Brodsky; +1 301-796-5179, brodsky@fda.hhs.gov

Co-Chair: Edward Helton; +1 301-480-4290, heltone2@mail.nih.gov

Co-Chair: Myron Finseth; +1 763-242-3703 myron.finseth@medtronic.com

Co-Chair: Hugh Glover; Skype: hugh_bw, hugh_glover@bluewaveinformatics.co.uk

Project Facilitator: Mead Walker

Publishing Facilitator: Myron Finseth

Vocab Facilitator: Julie James

Work Products and Contributions to HL7 Processes

The BR&R performs the bulk of its work through projects with a clear line of sight to its scope. Examples include BRIDG (domain analysis model supporting research) and RPS (exchange message supporting medical product application submissions to regulators).

This Work Group will facilitate the development of common standards and the maintenance and enhancement of the research-focused domain analysis model for clinical research information management across a variety of organizations, including national and international government agencies and regulatory bodies, private researchers and research organizations, sponsored research, CROs and other interested entities. A shared semantic view is essential if the clinical research community, both for itself and as part of the larger Healthcare and life sciences communities, is to achieve computable semantic interoperability.

The BR&R will seek to assure that related or supportive standards produced by other HL7 groups are robust enough to accommodate their use in regulated clinical research through participation as appropriate, including ballots. The group will also monitor information interchange standards developed outside of HL7, and attempt harmonization of information content and representation of such standards with the HL7 content and representation.

The BR&R’s charge includes the maintenance of BR&R-produced standards until their useful life has been exceeded, either through discontinuance of use or through supercession by later versions of the standard. The portfolio of standards will be reviewed annually for active use, obsolescence, and potential need for change. When a standard is identified for withdrawal, the BR&R will make efforts to communicate to users or potential users of that standard well in advance of any withdrawal action.

The BR&R will develop specifications using the principles and language of the Services Aware Interoperability Framework (SAIF) Canonical Definition (CD) and the restrictions and specializations of the HL7 SAIF Implementation Guide (IG) to ensure traceability from conceptual to logical to implementable specifications.

The term “regulated” or “regulation” refers to human and animal medical products and foods regulation.

Formal Relationships with Other HL7 Groups

Clinical Genomics Clinical Interoperability Council Clinical Quality Information Electronic Health Record Emergency Care FHIR Health Care Devices Orders and Observations Patient Care Patient Safety Pharmacy Public Health and Emergency Response Structured Documents

Formal Relationships with Groups Outside of HL7

The BR&R maintains liaison relationships with appropriate national and international standard bodies subject to the approval of the HL7 Board, including at minimum CDISC and ISO TC 215 (and by reference, CEN TC 251).

BR&R BRIDG Re-architecture and Usability Subgroup

The objective of this BR&R subgroup is to develop a plan to improve the usability of the BRIDG UML model.

Deliverables:


Subgroup Working Documents


TCB and BR&R Lab Model Discussions

Report_back_from_Meeting_Tue_Feb 20th, 2018

Report_back_from_Meeting_Wed_Apr 18th, 2018